Guangxi Wuzhou Zhongheng Group (600252) Fundamentals 2026 — Revenue Analysis | SniperIQ
Guangxi Wuzhou Zhongheng Group (600252) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥6.8B, trading at ¥2.15 on the SHH. This SniperIQ fundamentals page covers Guangxi Wuzhou Zhongheng Group's valuation, profitability (net margin -21.9%), revenue (¥1.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Guangxi Wuzhou Zhongheng Group's market cap?
Guangxi Wuzhou Zhongheng Group (600252) has a market capitalization of approximately ¥6.8B, trading at ¥2.15 on the SHH. Market cap moves with the live share price.
What is Guangxi Wuzhou Zhongheng Group's P/E ratio?
Guangxi Wuzhou Zhongheng Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Guangxi Wuzhou Zhongheng Group?
Guangxi Wuzhou Zhongheng Group runs a net profit margin of -21.9%, a gross margin of 39.6%, and an operating margin of -31.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Guangxi Wuzhou Zhongheng Group generate?
Guangxi Wuzhou Zhongheng Group reported revenue of ¥1.7B for fiscal year 2025, with net income of -¥357M and earnings per share (EPS) of -0.11. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Guangxi Wuzhou Zhongheng Group pay a dividend?
Guangxi Wuzhou Zhongheng Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Guangxi Wuzhou Zhongheng Group financially healthy?
Guangxi Wuzhou Zhongheng Group carries a debt-to-equity ratio of 0.40x and a current ratio of 2.13x, with a market beta of 0.13. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Guangxi Wuzhou Zhongheng Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Guangxi Wuzhou Zhongheng Group (600252) the key facts are: market cap ¥6.8B, revenue ¥1.7B, 52-week range 1.71-3.23. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Guangxi Wuzhou Zhongheng Group's full fundamentals live
Get Guangxi Wuzhou Zhongheng Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.